We wouldn't blame Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders if they were a little worried about the fact that Javier San Martin, the Chief Medical Officer recently netted about US$567k selling shares at an average price of US$28.80. That's a big disposal, and it decreased their holding size by 36%, which is notable but not too bad.

See our latest analysis for Arrowhead Pharmaceuticals

The Last 12 Months Of Insider Transactions At Arrowhead Pharmaceuticals

Notably, that recent sale by Javier San Martin is the biggest insider sale of Arrowhead Pharmaceuticals shares that we've seen in the last year. That means that an insider was selling shares at around the current price of US$28.96. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

In the last year Arrowhead Pharmaceuticals insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Arrowhead Pharmaceuticals

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Arrowhead Pharmaceuticals insiders own about US$92m worth of shares. That equates to 3.0% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At Arrowhead Pharmaceuticals Tell Us?

Insiders haven't bought Arrowhead Pharmaceuticals stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. So we'd only buy after careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Arrowhead Pharmaceuticals. While conducting our analysis, we found that Arrowhead Pharmaceuticals has 1 warning sign and it would be unwise to ignore this.

But note: Arrowhead Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.